SEC Tracker
Get the app

Spero Therapeutics SPRO

Spero Therapeutics appoints new director

Spero Therapeutics (SPRO) filed an 8-K with the SEC on Nov 10, 2026, 5:31 pm ET. Source: the filing on SEC EDGAR.

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Patrick Vink resigns as director and committee chair
  2. William Ho appointed as Class II director and Development Committee member
  3. Dr. Ho receives $40,000 annual cash retainer and 100,000 stock options

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Spero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.